Annals of Internal Medicine embargoed news; Catheter ablation superior to standard drug

December 24, 2018

1. Catheter ablation superior to standard drug therapy for heart failure

Abstract: http://annals.org/aim/article/doi/10.7326/M18-0992

URLs go live when the embargo lifts

A meta-analysis of randomized controlled trials found that catheter ablation was superior to conventional drug therapy alone for patients with atrial fibrillation and heart failure. Findings are published in Annals of Internal Medicine.

Atrial fibrillation is associated with thromboembolic stroke, systemic embolism, and decompensated heart failure. Catheter ablation is an established therapeutic strategy for atrial fibrillation, but guidelines recommend caution in certain patients. The benefits and harms of catheter ablation versus drug therapy for patients with atrial fibrillation have not been firmly established.

Researchers from Icahn School of Medicine at Mount Sinai reviewed six published randomized controlled trials to compare the benefits and harms between catheter ablation and standard drug therapy (rate or rhythm control medications) in adult patients with atrial fibrillation and heart failure. Their analysis showed that compared to medication, catheter ablation was associated with reductions in all-cause mortality and heart failure hospitalizations and improvements in left ventricular ejection fraction; quality of life; cardiopulmonary exercise capacity; and 6-minute walk test distance, with no statistically significant increase in serious adverse events.

The major adverse events rates observed in the pooled analysis were 7.2 percent in the ablation group and 3.8 percent in the standard therapy group. Despite the complications associated with catheter ablation, the authors explain that the long-term benefits in all-cause mortality, heart failure hospitalizations, and overall clinical outcomes must be weighed in clinical decision making.

Media contact: For an embargoed PDF, please contact Lauren Evans at laevans@acponline.org. To interview the lead author, Vivek Reddy, MD, please contact Wendi Chason at wendi.chason@mountsinai.org.

2. Proposed technique prevents confused patients from dislodging central line


Abstract: http://annals.org/aim/article/doi/10.7326/L18-0439

URLs go live when the embargo lifts

A proposed technique for placing a central venous catheter that may prevent confused patients from pulling it out or dislodging it easily. Findings from a case report are published in Annals of Internal Medicine.

Sometimes patients, particularly confused patients, dislodge or pull out central venous catheters inadvertently or intentionally. Although this occurrence is uncommon, it is not rare, and it may have negative consequences.

Physicians from Beth Israel Deaconess Medical Center and Harvard Medical School saw a 77-year-old patient with waxing and waning mental status who required dialysis for chronic kidney failure. The patient became confused and repeatedly pulled out his hemodialysis catheters. Since he was unsuitable for an arteriovenous access and the medical literature offered no solution, the physicians developed a novel technique. They placed a right external jugular vein catheter, tunneling subcutaneously to exit from the patient's upper back, near the midline, just below his neck. It was out of reach to the patient, but not in an area where it would cause pressure on his skin when he was lying on his back. It worked well enough that the authors suggest clinicians consider this placement when caring for patients at risk for central line dislodgement.

Media contact: For an embargoed PDF, please contact Lauren Evans at laevans@acponline.org. To interview the lead author, Robert S. Brown, MD, please contact Jacqueline Mitchell at jsmitche@bidmc.harvard.edu.
-end-
Also in this issue:

Testing Novel payment and Delivery Approaches Through the Veterans Health Administration's New Center for Innovation

Steven D. Pizer, PhD; Austin B. Frakt, PhD; Kyle Sheetz, MD, MS; Carolyn Clancy, MD

Ideas and Opinions


Abstract: http://annals.org/aim/article/doi/10.7326/M18-2225

American College of Physicians

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.